ABSTRACT
Aneurysmal subarachnoid hemorrhage (aSAH) is an important public health problem, with more than 25,000 cases occurring annually in the United States ( 1 ). Despite advances in medical therapy, aSAH remains a deadly disease. Although mortality among hospitalized patients has fallen from 50% to 20% over the past 25 years, patients are still frequently left with signifi cant cognitive and emotional disability ( 2,3 ). Despite these improvements in mortality, the burden of aSAH is magnifi ed by the fact that this disease primarily affects individuals in the prime of their lives, between the ages of 30 and 60 years ( 4 ).
